Publications, Pharmaceutical

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

The complexity of demonstrating bioequivalence in complex locally acting orally inhaled and nasal drug products is a barrier to the successful commercialization of generics.

This paper details a study to investigate the performance of a population bioequivalence (PBE) test based on particle size distribution measurements generated by morphologically directed Raman spectroscopy. Simulations of PBE trials were conducted across a range of median particle size and span values. Trial optimization strategies are presented based on the observed data and the general applicability of the approach is underlined. Appropriate trial design can help generic developers to avoid underpowered studies when using complex in vitro techniques to demonstrate bioequivalence.

Download Publication
6 Oct 2020

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

8 May 2021

Developing a Dry Powder Formulation for Aptar Pharma Prohaler®

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
28 Apr 2021

Using Raman for the characterization of nasal drug suspension products

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
27 Apr 2021

The New Imperative

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
22 Apr 2021

Case Study – Pre-Clinical Respiratory Research with PADA

Case Studies, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 21 22 23 24 25 32
Back To Top